{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-020082","form_type":"8-K","ticker":"TCRX","cik":"0001783328","company_name":"TScan Therapeutics, Inc.","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.550550+00:00","generated_at":"2026-06-15T06:49:39.909138+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"TScan reports Q1 net loss $22.6M; Amgen partnership adds $30M upfront, extends cash runway","bullets":["Net loss $22.6M vs $16.2M in Q1 2022; revenue $6.8M, up from $3.0M on Novartis collaboration wind-down.","Amgen partnership for Crohn's disease targets: $30M upfront, potential milestones >$500M; cash runway extended into Q3 2024.","Phase 1 heme study: patients enrolled in all three arms; TSC-101 cleared for second dose level (two doses 40 days apart).","Cash and equivalents $95.6M at Mar 31, 2023; combined with Amgen upfront supports operations into Q3 2024.","Appointed Dr. Barbara Klencke to Board of Directors; she previously led oncology development at Sierra/GSK."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-020082","json":"https://secwatch.observer/filing/0000950170-23-020082.json","markdown":"https://secwatch.observer/filing/0000950170-23-020082.md","text":"https://secwatch.observer/filing/0000950170-23-020082.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783328/000095017023020082/0000950170-23-020082-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783328/000095017023020082/tcrx-20230510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T06:49:39.909138+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2de78654879147025cc17732a610fe5ac5194faf","claim":"TScan Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2023.","evidence_excerpt":"On May 10, 2023, TScan Therapeutics, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783328/000095017023020082/0000950170-23-020082-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}